ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.

HCM.GB HUTCHMED China Limited

310,00
16,00 (5,44%)
02 Mai 2024 - Geschlossen
Echtzeitdaten
Name Symbol Markt Aktientyp
HUTCHMED China Limited HCM.GB Aquis Stock Exchange Ordinary Share
  Änderung Änderung % Aktuell Zeit
16,00 5,44% 310,00 09:05:26
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
294,00 294,00 310,00 310,00 294,00
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
11.1.202408:00RNSNONHutchmed (China) Limited Sovleplenib NDA Granted Priority..
29.12.202309:30UKREGHutchmed (China) Limited Total Voting Rights
29.12.202309:30UKREGHutchmed (China) Limited Blocklisting Six Monthly Return
21.12.202311:00UKREGHutchmed (China) Limited Overseas Regulatory Announcement
13.12.202308:00RNSNONHutchmed (China) Limited Inclusion in National Reimbursement..
07.12.202311:04UKREGHutchmed (China) Limited Overseas Regulatory Announcement
01.12.202308:00RNSNONHutchmed (China) Limited Clinical Data to be Presented at..
30.11.202309:30UKREGHutchmed (China) Limited Total Voting Rights
09.11.202308:00UKREGHutchmed (China) Limited U.S. FDA Approval of FRUZAQLA(TM)..
24.10.202310:30UKREGHutchmed (China) Limited Vesting of awards under the LTIP
16.10.202310:30RNSNONHutchmed (China) Limited Clinical Data to be Presented at..
29.9.202310:30RNSNONHutchmed (China) Limited NDA Submission for Fruquintinib in..
29.9.202310:30UKREGHutchmed (China) Limited Total Voting Rights
14.9.202310:30UKREGHutchmed (China) Limited Director's Share Dealing
12.9.202310:30RNSNONHutchmed (China) Limited Phase IIIb Savolitinib Results at..
12.9.202308:00RNSNONHutchmed (China) Limited Patient Enrollment Completed for..
31.8.202310:30UKREGHutchmed (China) Limited Total Voting Rights
29.8.202308:00RNSNONHutchmed (China) Limited BTD in China for Savolitinib for..
21.8.202308:00UKREGHutchmed (China) Limited Sovleplenib Phase 3 Study Meets..
07.8.202310:30UKREGHutchmed (China) Limited Exercise of Share Options by a..
31.7.202313:00UKREGHutchmed (China) Limited Interim Results and Business..
20.7.202308:00RNSNONHutchmed (China) Limited Breakthrough Therapy Designation..
13.7.202310:30UKREGHutchmed (China) Limited Changes to Board and Technical..
10.7.202308:00RNSNONHutchmed (China) Limited Phase 1 Study of HMPL-415 Initiated
29.6.202310:30UKREGHutchmed (China) Limited Blocklisting Six Monthly Return
26.6.202310:30UKREGHutchmed (China) Limited HUTCHMED to Announce 2023 Half-Year..
16.6.202308:00UKREGHutchmed (China) Limited Phase III FRESCO-2 Results in The..
15.6.202316:39UKREGHutchmed (China) Limited MAA of Fruquintinib Validated by..
09.6.202311:30RNSNONHutchmed (China) Limited HUTCHMED Highlights Presentations..
06.6.202311:00UKREGHutchmed (China) Limited LTIP and Share Option Scheme
31.5.202310:30UKREGHutchmed (China) Limited Total Voting Rights
26.5.202308:00RNSNONHutchmed (China) Limited HUTCHMED Highlights Presentations..
26.5.202308:00UKREGHutchmed (China) Limited Fruquintinib NDA Granted Priority..
17.5.202310:30UKREGHutchmed (China) Limited Standard form for notification of..
12.5.202314:15UKREGHutchmed (China) Limited Annual General Meeting Poll Results
12.5.202310:30UKREGHutchmed (China) Limited Board of Directors and Board..
10.5.202310:30UKREGHutchmed (China) Limited Appointment of Independent NED

Kürzlich von Ihnen besucht

Delayed Upgrade Clock